IBOV 187,958.63 ▲ 1.25% IPSA 11,300.24 ▼ 0.62% IPC MEX 64,479.96 ▼ 0.52% MERVAL 3,107,396 ▼ 0.09% COLCAP 2,580.41 ▼ 0.14% BVL PERÚ 60,702.89 ▼ 1.24% USD/BRL5.11▼ 0.06% USD/MXN16.97▲ 0.42% USD/CLP940.75▲ 1.41% USD/COP3,089▼ 0.90% USD/PEN3.37▲ 0.44% USD/ARS1,513▼ 0.08% USD/UYU40.24▲ 3.05% USD/PYG5,868▲ 2.26% USD/BOB12.36▲ 1.91% USD/DOP58.60▲ 0.17% USD/CRC447.58▲ 1.69% USD/GTQ7.63▲ 3.04% USD/HNL26.85▲ 0.57% USD/NIO36.62▲ 0.34% USD/VES825.67▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.73▲ 2.40% EUR/BRL5.93▲ 0.34% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 187,958.63 ▲ 1.25% IPSA 11,300.24 ▼ 0.62% IPC MEX 64,479.96 ▼ 0.52% MERVAL 3,107,396 ▼ 0.09% COLCAP 2,580.41 ▼ 0.14% BVL PERÚ 60,702.89 ▼ 1.24% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Thursday, September 10, 2026

Covid-19 Brazil

A Closer Look at mRNA COVID-19 Vaccine Safety: Striking Findings from Japan

By · August 15, 2024 · 2 min read

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “YPF sells US$1.2bn bond, Argentina's biggest since 2015”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

In Japan, Keisuke Takada and his team analyzed a national database for vaccine-related adverse effects.

They focused on mRNA COVID-19 vaccines from Pfizer and Moderna. Their comprehensive study, spanning nearly two decades, has identified a significant connection between certain vaccines and heart issues.

Specifically, conditions like myocarditis and pericarditis are more commonly observed among young men following vaccination.

A Closer Look at mRNA COVID-19 Vaccine Safety: Striking Findings from Japan.
A Closer Look at mRNA COVID-19 Vaccine Safety: Striking Findings from Japan.
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →
  • The dataset documents 880,999 incidents within a population of 125.1 million.
  • Researchers noted 1,846 cases of myocarditis and 761 of perikarditis.
  • Calculated odds ratios reveal strikingly high associations:
    • About 30 times higher for myocarditis.
    • About 22 times higher for perikarditis compared to unvaccinated individuals.
    • Moderna’s vaccine shows even higher risks.

The study highlights that these adverse events mainly affected males under 30, typically manifesting within a week after vaccination.

Many cases resolved, but reports also documented severe outcomes and deaths.

The Implications

These findings suggest a higher frequency of severe cardiac events associated with mRNA vaccines in certain populations.

They trigger a reevaluation of vaccine use, especially in groups at heightened risk.

Although the results do not prove causation definitively, they signal the need for urgent attention and further investigation.

This analysis is vital as it helps weigh the benefits of widespread vaccination against potential risks to specific groups.

It highlights the importance of continuous monitoring and research to ensure vaccine safety and efficacy for all segments of the population.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.